MAPT and Alzheimer disease: If an individual has an abnormal Aβ deposition evidence, but a biomarker for tau is not available, then the individual is placed into the “Alzheimer's continuum.” The diagnostic framework is a purely biological definition of AD that relies on biomarkers.